Head and neck carcinoma (HNC), the sixth most frequent kind of cancer worldwide, is a group of biologically similar cancers that originate from head and neck regions such as oral cavity, pharyngeal cavity, and larynx[@b1]. Previous reports showed that life-style factors such as smoking, drinking, betel quid chewing, papilloma virus infection, and exposure to toxic substances are possible etiological risk factors for HNC[@b2][@b3]. Nevertheless, though many individuals are exposed to these external factors, HNC develops only in a small proportion of the exposed people, indicating that intrinsic factors such as genetic polymorphism might play critical roles in its carcinogenic mechanisms.

Generally, folate plays a fundamental role of providing methyl groups for *de novo* deoxynucleoside synthesis and for intracellular methylation reactions in humans[@b4]. Low folate levels may result in uracil misincorporation during DNA synthesis, impaired DNA repair and chromosomal damage[@b5]. Several key enzymes were involved in the folate metabolism and their functions may have an effect on folate levels and DNA methylation. Methylenetetrahydrofolate reductase (*MTHFR*), a key enzyme for intracellular folate hemeostasis and metabolism, catalyses the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate that is the primary circulating form of folate, providing methyl groups for the methylation of homocysteine to methionine[@b6][@b7]. A common variation of *MTHFR* (rs1801133), C677T in exon 4 (Ala222Val), may be implicated in tumorigenesis with alteration of *MTHFR* enzyme activity[@b8]. The homozygous genotype 677TT has been indicated to have only 30% of the *MTHFR* enzyme activity of the 677CC wild-type genotype[@b9]. Therefore, alteration of the enzyme activity resulted from the polymorphism has been thought to be associated with cancer progression and development[@b10].

Published data on the association of *MTHFR* polymorphism with HNC have generated inconclusive results. Clarifying this association may help us better understand the possible risk of HNC and therefore contribute to its prevention. Previously, we assessed the relationship between *MTHFR* polymorphism and oral cancer risk[@b11]. Recently, several original studies have been reported. Thus, in the present study, we performed an updated meta-analysis including the recent investigations that were conducted on head and neck cancers.

Materials and methods
=====================

Literature search strategy
--------------------------

The meta-analysis was presented according the PRISMA-MOOSE statement. We carried out a search in the internet covering well-known biomedical databases such as Medline, EMBASE, and CNKI without a language limitation. Papers published up to Jun 1, 2014 were included. The literature selection was performed from Jun 1, 2014 to Jun 30, 2014. The following keywords were used for searching: *methylenetetrahydrofolate reductase, MTHFR, head and neck, oral, pharynx, larynx, thyroid, mouth, neoplasm, tumor, cancer, variation* and *polymorphism*. All searched studies were retrieved and the bibliographies were checked for other relevant publications. Review articles and bibliographies of other relevant studies identified were hand searched to find additional eligible studies.

Inclusion criteria
------------------

The following criteria were used for the literature selection: First, studies should concern the association of *MTHFR* C677T polymorphism with HNC risk; second, studies should be case-control or cohort designed; third, papers must offer the size of the sample, odds ratios (ORs) and their 95% confidence intervals (CIs), the genetic distribution or the information that can help infer the results. After deliberate searching, we reviewed all papers in accordance with the criteria defined above for further analysis.

Data extraction
---------------

Information was carefully extracted from all eligible papers by two of the authors (XZ and JS) independently according to the inclusion criteria mentioned above. If their results were conflicting, an agreement was reached following a discussion. If a consensus could not be reached, another author (DL) was consulted to resolve the dispute and then a final decision was made by the majority of the votes. The extracted data were entered into a database.

Statistical analysis
--------------------

The odds ratio (OR) of *MTHFR* C677T polymorphisms and HNC risk was estimated for each study. The pooled ORs were performed for a homozygote comparison model (TT versus CC), a dominant model (TT + CT versus CC) and a recessive model (TT versus CT + CC), respectively. For detection of any possible sample size biases, the OR and its 95% confidence interval (CI) to each study was plotted against the number of participants respectively. For assessment of the heterogeneity between studies, two indexes were calculated. One was *I*^*2*^ metric, with *I*^*2*^ = 0-25% indicating no heterogeneity, *I*^*2*^ = 25-50% indicating moderate heterogeneity, and *I*^*2*^ \> 50% indicating large heterogeneity[@b12]. The other index was a Chi-square based Q statistic test. If the result of the Q-test was *P* \> 0.1 (indicating no heterogeneity), ORs were pooled according to the fixed-effect model (Mantel-Haenszel), Otherwise, the random-effect model (DerSimonian and laird) was used. The significance of the pooled ORs was determined by Z-test. The Hardy-Weinberg equilibrium (HWE) was assessed via Fisher's exact test. Publication bias was assessed by visual inspection of funnel plots[@b13], in which the standard error of log (OR) of each study was plotted against its log (OR). The symmetry of the funnel plot was further evaluated by Egger's linear regression test[@b14]. An asymmetric plot indicates a possible publication bias. Statistical analysis was conducted by using the STATA 11.0 software (Stata Corporation, Texas).

Results
=======

Study characteristics
---------------------

Publications relevant to the key words were retrieved and screened originally. A total of ninety-seven studies were searched and screened for retrieval, of which sixty-seven irrelevant studies were excluded. Then, three review articles[@b15][@b16][@b17] were excluded. Next, three studies that were not case-control designed[@b18][@b19][@b20] (also not cohort designed) were discarded. Thus, a total of twenty-four papers were included for data extraction. Nevertheless, one duplicate publication[@b21] was further excluded. Lastly, twenty-three case-control studies[@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44] were selected ([Fig. 1](#f1){ref-type="fig"}).

All the included studies were written in English except for one study in Chinese[@b30]. We established a database according to the extracted information from each article. The relevant information was listed in [Table 1](#t1){ref-type="table"}. According to the lists, the first author and the number and characteristics of cases and controls for each study as well as other necessary information were presented. As shown in this table, the selected studies involved cancers originated from oral cavity, pharynx, larynx and thyroid.

In the included studies, there were eight groups of Caucasians[@b23][@b27][@b29][@b33][@b38][@b41][@b42][@b43], eight of Asians[@b22][@b30][@b32][@b35][@b37][@b39][@b40][@b44] and seven of mixed populations[@b24][@b25][@b26][@b28][@b31][@b34][@b36]. Information about smoking could be extracted from five studies[@b22][@b25][@b30][@b39][@b40] and data regarding drinking status were also available from five studies[@b23][@b25][@b37][@b38][@b39]. The distributions of *MTHFR* genotype of the included studies were also presented ([Table 2](#t2){ref-type="table"}). Of note, the data about CT and TT in the study by Hsiung *et al.*[@b26] were combined as TT + CT, and therefore, the relevant data were only included in the dominant model for the whole evaluation. The genetic distributions of the control groups were consistent with HWE except for those in four studies[@b24][@b33][@b41][@b42].

Meta-analysis results
---------------------

We evaluated the heterogeneity for the homozygote comparison model (TT versus CC), dominant model (TT + CT versus CC) and recessive model (TT versus CT + CC), respectively. As shown in [Table 3](#t3){ref-type="table"}, the heterogeneity for the overall data was significant in the three models, respectively, because the P value was less than 0.1 for Q-tests and I-squared values indicated more than moderate heterogeneity. Therefore, the random-effect models were used in the present meta-analysis.

[Table 3](#t3){ref-type="table"} lists the main results of the meta-analysis. The overall data in the homozygote comparison model (OR = 1.16; 95%CI = 0.93-1.45), the dominant (OR = 1.05; 95%CI = 0.90-1.21) and the recessive models (OR = 1.14; 95%CI = 0.93-1.38) failed to reveal a marked association between *MTHFR* C677T polymorphism with HNC risk ([Fig. 2](#f2){ref-type="fig"}).

Similar results were observed in the subgroups regarding ethnicity, source of controls, sample size, tumor type and smoking status. Nevertheless, in the subgroup analysis concerning drinking status, elevated risk was shown in the heavy drinking subgroup under the homozygote comparison model (OR = 3.11; 95%CI = 1.52-3.02), indicating that TT carriers who have a heavy drinking history might have an increased HNC risk.

Sensitivity analysis and Bias diagnostics
-----------------------------------------

To test the stability of the overall results, we first excluded the studies whose genetic distributions in controls markedly deviated from HWE, given that the deviation might result in any bias[@b45]. The significance of the overall data in the three models was also not statistically altered. Then, we also conducted one-way sensitivity analysis[@b46] by deleting a single study each time. The statistical significance of the results was not also altered (data not shown), confirming the stability and credibility of the results.

Funnel plots were created for assessment of possible publication bias. Then, Egger's linear regression tests were used to assess the symmetry of the plots. As a result, the data suggest that the funnel plots were symmetrical for the three models (homozygote comparison model: t = 0.13, P \> 0.05; dominant model: t = −1.29, P \> 0.05; recessive model: t = 0.87, P \> 0.05), suggesting that the publication bias may have little influence on the results ([Fig. 3](#f3){ref-type="fig"}).

Discussion
==========

The effects of *MTHFR* C677T polymorphism on cancer risk were controversial. Recent published meta-analyses showed that 677 C \> T variation might contribute to the development of breast and esophageal cancer[@b47][@b48]; however, a decreased cancer risk was observed in colorectal cancer[@b49]. Thus, *MTHFR* C677T polymorphism may play various roles in different carcinomas. In the present study, though the overall results failed to suggest a relationship between *MTHFR* C677T variation and HNC risk, the subgroup analysis indicated that homozygous 677TT might be associated with increased susceptibility to HNC in individuals who have a heavy drinking history.

Considering the possible effects of the confounding factors on the overall data, we tried to carry out subgroup analyses. In subgroup analysis according to ethnicity, no significant association between *MTHFR* 677T allele with HNC risk was observed among the three subgroups. The results were in line with the overall data, indicating that the effects of discrepancies among different ethnicities on the results were not evident.

When the data were stratified by source of controls and sample size, respectively, the results were not significantly different from the whole results, indicating that these two factors have little influence on the results. Likewise, in the subgroup stratified by tumor type, the results were in accordance with the overall data, implying that the dissimilarity of tumor types rarely affect the pooled results.

Whether chronic smoking interacts with folate status in the pathophysiologic process of disorders remains controversial[@b50]. Evidence suggests that low serum folic acid concentrations were commonly detected in smokers[@b51]. Nevertheless, cytological damage, an early event of carcinogenesis, is evident in the mouths of smokers, but it dose not correlate with folate status[@b52]. In the present meta-analysis, data about smoking status could be extracted from five included studies. The results showed that elevated risk was observed in neither the never-smoking subgroup nor the ever-smoking subgroup. The data failed to reveal an obvious interaction of smoking and *MTHFR* variation for HNC risk. However, when the data were divided by drinking status, elevated risk was shown in the heavy drinking subgroup under the homozygote comparison model. The data were in line with our previous meta-analysis about oral cancer[@b11]. The underlying mechanisms were unclear. *MTHFR* 677C → T polymorphism might play different roles for cancer risk according to the folate levels. It might reduce cancer risk when folate status is normal[@b53] while lead to impaired stability and reduced activity of the enzyme under low folate conditions[@b54]. Notably, exposure to alcohol consumption might result in low folate status because chronic alcohol exposure may interfere with folate absorption by suppressing the folate carrier expression, thus decreasing the expression of folate transport proteins and reducing the hepatic uptake and renal conservation of circulating folate[@b55][@b56]. Also, alcohol might act as a folate antagonist that is responsible for abnormalities in folate-mediated one-carbon metabolism[@b57]. Moreover, folate depletion in mitochondria caused by chronic alcohol exposure might lead to abnormal DNA synthesis and DNA methylation that has been thought to be involved in the carcinogenesis process[@b58][@b59]. This might explain the interactions of alcohol with 677TT genotype in the genesis of HNC. However, only five of the selected studies concerned this issue. In the meantime, the data should be interpreted with care because of the limited sample sizes.

Evident heterogeneity was shown in every model for the overall data, and thus, random-effect models were used to pool the data. Nevertheless, significant heterogeneities were removed in some subgroups while observed in other subgroups, indicating that the heterogeneities may be multifactorial. Besides the confounding factors considered in the subgroup analysis, other factors such as age, gender and life-style factors might contribute to the heterogeneities.

Several limitations might be involved in this meta-analysis. First, only publications written in English and Chinese were searched and selected. It is possible that articles written in other languages that might meet the inclusion criteria were missed. Thus, inevitable publication biases might exist though the funnel plots were tested to be symmetrical. Second, subgroup analyses regarding age, gender and other risk factors such as virus infection status and betel quid chewing have not been conducted because the data in the primary literature were insufficient. Third, hospital-based controls were used in some of the included studies, leading to non-differential misclassification bias. Moreover, the controls in some studies were not strictly matched to the cases. Therefore, any selection bias might have an influence on the overall results and future investigations with large sample sizes are required.

Despite the limitations, though the overall data of the present meta-analysis did not reveal an association of *MTHFR* C677T polymorphism with HNC risk, the subgroup analysis indicated that *MTHFR* 677TT alleles might increase HNC risk in individuals who have a heavy drinking history.
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###### Characteristics of studies included in the meta-analysis.

  **First Author**    **Publication Year**  **Number of Cases (male/female)**   **Number of Controls (male/female)**                                       **Type of controls**                                       **Mean age, year Cases/Controls**   **Racial decent**    **Types**    **Country**   **Ref No.**
  ------------------ ---------------------- ----------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------- ------------------- ------------- -------------- -------------
  Weinstein                   2002          519 (NA/NA)                         629 (NA/NA)                                             Healthy controls (Age-, gender- matched; population-based)                                63.2/61.0                   Caucasian       Oral cavity       USA       43
  Kureshi                     2004          50 (33/17)                          54 (30/24)                                              Healthy controls (Age-, gender- matched; population-based)                                51.3/50.2                     Mixed          Combined       Pakistan    28
  Capaccio                    2005          65 (57/8)                           100 (88/12)                               Healthy controls (Age-, gender-, drinking-, smoking status- matched; population-based)                  61.3/58.8                   Caucasian        Combined        Italy      23
  Neumann                     2005          537 (411/126)                       545 (401/144)                                   Non-cancerous controls (Age-,sex-, smoking status-matched; hospital-based)                          NA/NA                     Caucasian        Combined         USA       29
  Vairaktaris                 2006          110 (94/16)                         120 (102/18)                                         Healthy controls (Age-, sex, ethnicity-matched; population-based)                            52.1/51.5                   Caucasian       Oral cavity   GreekGerman   41
  Hsiung                      2007          278 (193/85)                        526 (377/149)                                  Healthy controls (Age-, gender, town of residence-matched; population-based)                       60.1/61.0                     Mixed          Combined         USA       26
  Reljic                      2007          81 (NA/NA)                          102 (37/65)                                                  Healthy controls (Age-matched; population-based)                                       NA/NA                     Caucasian        Combined       Croatia     33
  Suzuki                      2007          237 (188/49)                        711 (564/147)                                            Non-cancerous controls (Age-,sex-matched; hospital-based)                                57.9/58.4                     Asian          Combined        Japan      39
  Ni                          2008          207 (189/18)                        400 (362/38)                                               Healthy controls (Age-,sex-matched; population-based)                                    NA/NA                       Asian           Larynx         China      30
  Siraj                       2008          223 (NA/NA)                         513 (NANA)                                                   Healthy controls (Age-matched; population-based)                                       NA/NA                       Mixed           Thyroid     Saudi Arabia  36
  Solomon                     2008          126 (NA/NA)                         100 (NA/NA)                                                        Healthy individuals(population-based)                                          54.7/55.4                     Asian         Oral cavity      India      37
  Cao                         2010          529 (339/190)                       577 (367/210)                                        Healthy controls (Age-,sex-, ethnicity-matched; population-based)                            46.1/45.4                     Asian         Nasopharynx      China      22
  Kruszyna                    2010          131 (131/0)                         250 (250/0)                                                         Healthy controls (population-based)                                           59.4/56.8                   Caucasian         Larynx         Poland     27
  Rodrigues                   2010          100 (84/16)                         100 (76/24)                                                       Non-cancerous controls (hospital-based)                                         59.5/43.6                     Mixed          Combined        Brazil     34
  Fard-Esfahani               2011          154 (34/120)                        198 (50/148)                                                      Non-cancerous controls (hospital-based)                                           NA/NA                       Mixed           Thyroid         Iran      24
  Prasad                      2011          97 (27/70)                          241 (116/125)                                                       Healthy controls (population-based)                                             NA/NA                       Asian           Thyroid        India      32
  Sailasree                   2011          130 (88/42)                         139 (92/47)                                            Non-cancerous controls (Age-,gender-matched; hospital-based)                               58.0/57.0                     Asian         Oral cavity      India      35
  Supic                       2011          96 (72/24)                          162 (130/32)                                    Non-cancerous controls(Age-, gender-, ethnicity-matched; population-based)                        58.0/58.0                   Caucasian       Oral cavity      Serbia     38
  Tsai                        2011          620 (583/37)                        620 (572/48)                                        Healthy controls (Age-, gender-, habits-matched; population-based)                            65.5/63.5                     Asian         Oral cavity      China      40
  Galbiatti                   2012          322 (280/42)                        531 (384/147)                                                       Healthy controls (population-based)                                             NA/NA                       Mixed          Combined        Brazil     25
  Ozdemir                     2012          60 (11/49)                          50 (21/29)                                                          Healthy controls (population-based)                                           55.3/68.6                     Mixed           Thyroid        Turkey     31
  Vylliotis                   2013          160 (NA/NA)                         168 (NA/NA)                             Healthy controls (Age-, gender-, ethnicity-, working environment-matched; population-based)               58.5/54.7                   Caucasian       Oral cavity      Greece     42
  Kweon                       2014          2194 (404/1790)                     1669 (812/857)                                          Healthy controls (Age-, gender-, matched; population-based)                               50.6/52.2                     Asian           Thyroid        Korea      44

NA: not available

###### Distribution of *MTHFR* C677T genotype among cancer cases and controls.

                                          **Cases**   **Controls**   **HWE (control)**                                 
  --------------- ------ --------------- ----------- -------------- ------------------- --------- ----- ----- -------- ---------
  Weinstein        2002     PCR-RFLP         15            53               67             15      62    69    0.038    \> 0.05
  Kureshi          2004        PCR            0            12               22              4      18    32    0.420    \> 0.05
  Capaccio         2005        PCR           14            33               18             18      46    36    0.242    \> 0.05
  Neumann          2005        PCR           35           244               258            51      216   278   0.914    \> 0.05
  Vairaktaris      2006     PCR-RFLP          6            76               28             10      65    45    4.065    \< 0.05
  Hsiung           2007        PCR         149 (a)         \-               128          306 (a)   \-    218     \-       \-
  Reljic           2007     PCR-RFLP          9            27               45              8      59    35    6.074    \< 0.05
  Suzuki           2007      Taqman          36           113               88             128     331   252   1.121    \> 0.05
  Ni               2008     PCR-RFLP         64            95               48             61      187   152   0.078    \> 0.05
  Siraj            2008        PCR            1            18               30             13      126   372   0.351    \> 0.05
  Solomon          2008     PCR-RFLP         23            55               48             10      42    48    0.033    \> 0.05
  Cao              2010     PCR-RFLP         32           169               310            30      188   334   0.275    \> 0.05
  Kruszyna         2010     PCR-RFLP         10            52               69             20      104   126   0.052    \> 0.05
  Rodrigues        2010     PCR-RFLP         13            43               44             14      40    46    1.182    \> 0.05
  Fard-Esfahani    2011   Multiplex PCR      14            71               69              8      108   82    14.224   \< 0.05
  Prasad           2011     PCR-RFLP          1            10               86              1      12    228   3.311    \> 0.05
  Sailasree        2011     PCR-RFLP          1            8                92              1      29    108   0.400    \> 0.05
  Supic            2011     PCR-RFLP         14            32               50             16      66    80    0.193    \> 0.05
  Tsai             2011     PCR-RFLP         43           186               391            62      236   322   3.606    \> 0.05
  Galbiatti        2012     PCR-RFLP         45           147               130            55      250   226   1.358    \> 0.05
  Ozdemir          2012   Real-time PCR       7            25               28              3      14    33    0.781    \> 0.05
  Vylliotis        2013     PCR-RFLP          6            76               28             10      65    45    4.065    \< 0.05
  Kweon            2014     PCR-RFLP         422          1050              722            291     851   527   2.748    \> 0.05

(a): TT+CT

###### Main results of the pooled data in the meta-analysis

                                  **TT vs CC**        **(TT+CT) vs CC**   **TT vs (CT+CC)**                                                                                        
  ------------------- ----------- ------------------ ------------------- ------------------- ------- ------------------ ------- ------- ------- ------------------ ------- ------- -------
  Total                6354/7944  1.16 (0.93-1.45)          0.187               0.001         54.5%  1.05 (0.90-1.21)    0.540   0.000   68.7%  1.14 (0.93-1.38)   0.201   0.006   48.9%
  Ethnicity                                                                                                                                                                        
   Caucasian           1265/1545  0.95 (0.72-1.26)          0.742               0.860         0.0%   1.05 (0.81-1.38)    0.702   0.013   60.7%  0.92 (0.71-1.20)   0.533   0.511   0.0%
   Mixed               996/1968   1.41 (0.99-1.99)          0.054               0.489         0.0%   1.06 (0.85-1.33)    0.597   0.143   37.5%  1.38 (0.99-1.92)   0.056   0.415   0.2%
   Asian               4093/4431  1.24 (0.80-1.91)          0.331               0.000         80.3%  1.02 (0.78-1.34)    0.878   0.000   82.7%  1.21 (0.86-1.70)   0.279   0.001   73.1%
  Source of control                                                                                                                                                                
   PB                  5225/6252  1.24 (0.94-1.63)          0.121               0.001         59.0%  1.10 (0.92-1.32)    0.280   0.000   72.6%  1.21 (0.97-1.51)   0.086   0.019   46.4%
   HB                  1129/1692  0.88 (0.66-1.17)          0.377               0.392         2.5%   0.92 (0.71-1.19)    0.512   0.084   51.3%  0.91 (0.63-1.34)   0.646   0.181   36.1%
  Sample size                                                                                                                                                                      
   \<500               1400/1881  1.28 (0.97-1.68)          0.083               0.794         0.0%   1.07 (0.83-1.38)    0.613   0.001   62.2%  1.24 (0.95-1.60)   0.111   0.637   0.0%
   ≧500                4954/6063  1.09 (0.76-1.55)          0.641               0.000         80.6%  1.03 (0.85-1.23)    0.785   0.000   77.1%  1.08 (0.80-1.45)   0.630   0.000   76.5%
  Smoking status                                                                                                                                                                   
   Never-smoking        606/919   0.79 (0.45-1.37)          0.394               0.635         0.0%   0.90 (0.71-1.14)    0.376   0.605   0.0%   0.81 (0.52-1.27)   0.362   0.967   0.0%
   Ever-smoking        1223/1013  0.73 (0.49-1.10)          0.134               0.018         82.1%  1.24 (0.59-2.58)    0.573   0.000   94.2%  0.86 (0.62-1.21)   0.392   0.091   58.3%
  Drinking status                                                                                                                                                                  
   Light-drinking       201/474   0.78 (0.32-1.90)          0.588               0.455         0.0%   1.05 (0.75-1.46)    0.795   0.431   0.0%   0.99 (0.56-1.73)   0.961   0.717   0.0%
   Heavy-drinking       409/519   3.11 (1.52-3.02)          0.002               0.832         0.0%   1.94 (0.88-4.27)    0.099   0.001   82.1%  1.62 (0.46-5.73)   0.457   0.001   86.0%
  Tumor type                                                                                                                                                                       
   Oral cavity         1298/1406  1.03 (0.66-1.61)          0.883               0.099         43.8%  0.99 (0.67-1.46)    0.950   0.000   78.8%  0.99 (0.67-1.45)   0.939   0.168   34.0%
   Combined            1653/2667  0.97 (0.74-1.28)          0.830               0.293         17.9%  0.95 (0.79-1.15)    0.613   0.079   45.0%  0.97 (0.73-1.29)   0.827   0.191   31.0%
   Larynx               338/650   1.82 (0.51-6.44)          0.353               0.007         86.1%  1.37 (0.63-3.00)    0.432   0.006   86.8%  1.64 (0.64-4.17)   0.302   0.033   77.9%
   Thyroid             2554/2669  1.11 (0.92-1.32)          0.275               0.416         0.0%   1.28 (0.89-1.84)    0.185   0.020   65.8%  1.16 (0.99-1.37)   0.063   0.457   0.0%
   Nasopharynx          511/552   1.15 (0.68-1.94)          0.601                ---           ---   0.99 (0.78-1.27)    0.958    ---     ---   1.16 (0.70-1.94)   0.566   ---     ---

PB: population-based; HB: hospital-based

Heavy-drinking: \>46 g ethanol/week
